Histochemical characteristics on minimodeling-based bone formation induced by anabolic drugs for osteoporotic treatment

Yamamoto, Takanobu; Hasegawa, Tomoka; Fraitas, Paulo Henrique Luiz de; Hongo, Hiromi; Zhao, Shushan; Yamamoto, Tsuneyuki; Nasoori, Alireza; Abe, Miki; Maruoka, Haruhi; Kubota, Kosei; Morimoto, Yasuhito; Haraguchi, Masanobu; Shimizu, Tomohiro; Takahata, Masahiko; Iwasaki, Norimasa; Li, Minqi; Amizuka, Norio

doi:10.2220/biomedres.42.161

Cited by 5 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first to use this term was Frost ( Frost, 1966 ), and it was postulated later that minimodeling may continue in trabeculae throughout life ( Frost, 1990 ). It seems to contribute to a significant percentage of bone volume in special conditions such as CKD, parathyroidectomized and/or patients with ABD, and it has been popularized with the advent of new dual medications against OP, such as romosozumab ( Yamamoto et al, 2021 ). Increased mineralization of the minimodelling surface at the endocortical surface has also been observed in dialysis patients with ABD treated with the non-calcium-based phosphate binder lanthanum carbonate ( Yajima et al, 2013 ).…”

Section: Adynamic Bone Diseasementioning

confidence: 99%

Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis

Aguilar,

Gifre,

Ureña-Torres

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a highly prevalent disease that has become a public health problem. Progression of CKD is associated with serious complications, including the systemic CKD-mineral and bone disorder (CKD-MBD). Laboratory, bone and vascular abnormalities define this condition, and all have been independently related to cardiovascular disease and high mortality rates. The “old” cross-talk between kidney and bone (classically known as “renal osteodystrophies”) has been recently expanded to the cardiovascular system, emphasizing the importance of the bone component of CKD-MBD. Moreover, a recently recognized higher susceptibility of patients with CKD to falls and bone fractures led to important paradigm changes in the new CKD-MBD guidelines. Evaluation of bone mineral density and the diagnosis of “osteoporosis” emerges in nephrology as a new possibility “if results will impact clinical decisions”. Obviously, it is still reasonable to perform a bone biopsy if knowledge of the type of renal osteodystrophy will be clinically useful (low versus high turnover-bone disease). However, it is now considered that the inability to perform a bone biopsy may not justify withholding antiresorptive therapies to patients with high risk of fracture. This view adds to the effects of parathyroid hormone in CKD patients and the classical treatment of secondary hyperparathyroidism. The availability of new antiosteoporotic treatments bring the opportunity to come back to the basics, and the knowledge of new pathophysiological pathways [OPG/RANKL (LGR4); Wnt-ß-catenin pathway], also affected in CKD, offers great opportunities to further unravel the complex physiopathology of CKD-MBD and to improve outcomes.

show abstract

Section: Adynamic Bone Diseasementioning

confidence: 99%

Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis

Aguilar,

Gifre,

Ureña-Torres

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

show abstract

Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis

Meng,

Ma,

Jiang

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance. Eldecalcitol (ED‐71), a novel drug for treating osteoporosis, still requires research to overcome high‐frequency delivery and low‐utilization. Here, a bone‐targeting and multishelled nanoparticles are developed for step‐wise release of ED‐71. The nanoparticles are achieved by using the chitosan/alginate outer layer as protective barrier against gastric acid, pectin middle layer as adhesive agent that improved intestinal penetration, and ethylene diamine tetraacetic acid‐grafted mesoporous silica nanomaterials core as bone‐targeting nanocarriers. After oral administration, the ED‐71‐loaded nanoparticles (ME‐ED‐71@PCA) promotes osteogenic differentiation of bone marrow mesenchymal stem cells by reducing intracellular oxidative stress, and inhibits the osteoclast differentiation. ME‐ED‐71@PCA improves bone mass in ovariectomized‐mice by promoting osteogenesis and inhibiting osteoclastogenesis, and the efficacy is more pronounced than ED‐71 alone. ME‐ED‐71@PCA exhibits satisfactory therapeutic performance due to its step‐wise drug release and bone‐targeting compared to ED‐71 administration, providing a new approach to re‐establish bone metabolic homeostasis in PMOP.

show abstract

Zuo Gui Wan Promotes Osteogenesis via PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation

Yang,

Zhang,

Wang

et al. 2023

CURR MED SCI

View full text Add to dashboard Cite

Histochemical characteristics on minimodeling-based bone formation induced by anabolic drugs for osteoporotic treatment

Cited by 5 publications

References 38 publications

Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis

Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis

Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis

Zuo Gui Wan Promotes Osteogenesis via PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation

Contact Info

Product

Resources

About